Article Information
History
- June 30, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Shoji Hashimoto1,*,
- Heita Kitajima1,*,
- Tsuyoshi Arai1,
- Yoshitaka Tamura1,
- Takayuki Nagai1,
- Hiroshi Morishita1,
- Hiroto Matsuoka1,
- Yuki Han1,
- Seijiro Minamoto1,
- Tomonori Hirashima1,
- Tomoki Yamada1,
- Yozo Kashiwa1,
- Makoto Kameda1,
- Seiji Yamaguchi1,
- Kazuko Uno2,
- Emi Nakayama3,
- Tatsuo Shioda3,
- Kazuyuki Yoshizaki4,
- Sujin Kang5,
- Tadamitsu Kishimoto5 and
- Toshio Tanaka1,†
- 1Osaka Prefecture Hospital Organization Osaka Habikino Medical Center, Osaka 583-3588, Japan
- 2Louis Pasteur Center for Medical Research, Kyoto 606-8225, Japan
- 3Department of Viral Infection, Research Institute for Microbial Diseases, Osaka University, Osaka 565-0871, Japan
- 4Institute of Scientific and Industry Research, Osaka University, Osaka 565-0871, Japan
- 5Laboratory of Immune Regulation, Immunology Frontier Research Center, Osaka University, Osaka 565-0871, Japan
- ↵†Correspondence to: Toshio Tanaka MD, Ph.D. Osaka Prefectural Hospital Organization Osaka Habikino Medical Center, 3-7-1 Habikino, Habikino City, Osaka 583-8588, Japan mail: ttanak{at}ra.opho.jp
↵* These authors contributed equally to this work.
Posted June 30, 2020.
A retrospective study evaluating efficacy and safety of compassionate use of tocilizumab in 13 patients with severe-to-critically ill COVID-19: analysis of well-responding cases and rapidly-worsening cases after tocilizumab administration
